These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 33904521)

  • 1. Striatin genotype-based, mineralocorticoid receptor antagonist-driven clinical trial: study rationale and design.
    Stone IB; Green JAEM; Koefoed AW; Hornik ES; Williams JS; Adler GK; Williams GH
    Pharmacogenet Genomics; 2021 Jun; 31(4):83-88. PubMed ID: 33904521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatin heterozygous mice are more sensitive to aldosterone-induced injury.
    Garza AE; Trefts E; Katayama Rangel IA; Brooks D; Baudrand R; Moize B; Romero JR; Ranjit S; Treesaranuwattana T; Yao TM; Adler GK; Pojoga LH; Williams GH
    J Endocrinol; 2020 Jun; 245(3):439-450. PubMed ID: 32229698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variants in striatin gene are associated with salt-sensitive blood pressure in mice and humans.
    Garza AE; Rariy CM; Sun B; Williams J; Lasky-Su J; Baudrand R; Yao T; Moize B; Hafiz WM; Romero JR; Adler GK; Ferri C; Hopkins PN; Pojoga LH; Williams GH
    Hypertension; 2015 Jan; 65(1):211-217. PubMed ID: 25368024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatin Gene Polymorphic Variants Are Associated With Salt Sensitive Blood Pressure in Normotensives and Hypertensives.
    Gupta T; Connors M; Tan JW; Manosroi W; Ahmed N; Ting PY; Garza AE; Romero JR; Hopkins PN; Williams JS; Williams GH
    Am J Hypertens; 2017 Dec; 31(1):124-131. PubMed ID: 28985281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical Role of Striatin in Blood Pressure and Vascular Responses to Dietary Sodium Intake.
    Garza AE; Pojoga LH; Moize B; Hafiz WM; Opsasnick LA; Siddiqui WT; Horenstein M; Adler GK; Williams GH; Khalil RA
    Hypertension; 2015 Sep; 66(3):674-80. PubMed ID: 26169051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.
    Fernet M; Beckerman B; Abreu P; Lins K; Vincent J; Burgess E
    Vasc Health Risk Manag; 2018; 14():233-246. PubMed ID: 30275698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats.
    Nakamura T; Fukuda M; Kataoka K; Nako H; Tokutomi Y; Dong YF; Yamamoto E; Yasuda O; Ogawa H; Kim-Mitsuyama S
    Hypertens Res; 2011 Jul; 34(7):817-24. PubMed ID: 21471977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
    White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA
    Hypertension; 2003 May; 41(5):1021-6. PubMed ID: 12682082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysine-Specific Demethylase-1 Deficiency Increases Agonist Signaling Via the Mineralocorticoid Receptor.
    Treesaranuwattana T; Wong KYH; Brooks DL; Tay CS; Williams GH; Williams JS; Pojoga LH
    Hypertension; 2020 Apr; 75(4):1045-1053. PubMed ID: 32160100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Thrombotic Responses Are Associated With Striatin Deficiency and Aldosterone.
    Gromotowicz-Poplawska A; Flaumenhaft R; Gholami SK; Merrill-Skoloff G; Chabielska E; Williams GH; Romero JR
    J Am Heart Assoc; 2021 Nov; 10(22):e022975. PubMed ID: 34729990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
    White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
    Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
    Du J; Fan YY; Hitomi H; Kiyomoto H; Kimura S; Kong CZ; Noma T; Kohno M; Nishiyama A; Nakano D
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
    Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
    Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial.
    Raman SV; Hor KN; Mazur W; Cardona A; He X; Halnon N; Markham L; Soslow JH; Puchalski MD; Auerbach SR; Truong U; Smart S; McCarthy B; Saeed IM; Statland JM; Kissel JT; Cripe LH
    J Am Heart Assoc; 2019 Oct; 8(19):e013501. PubMed ID: 31549577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
    Hollenberg NK; Williams GH; Anderson R; Akhras KS; Bittman RM; Krause SL
    Arch Intern Med; 2003 Jul; 163(13):1543-8. PubMed ID: 12860576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
    Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.
    Arai K; Tsuruoka H; Homma T
    Eur J Pharmacol; 2015 Dec; 769():266-73. PubMed ID: 26607463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
    Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
    J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension.
    Schneider A; Schwab J; Karg MV; Kalizki T; Reinold A; Schneider MP; Schmieder RE; Schmidt BM
    J Hypertens; 2017 May; 35(5):1086-1092. PubMed ID: 28118280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.